Evidence map›Paper›PMID 37626085›Full record

ArticleScientific reports2023

Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab')

Stephen Findlay-Wilson, Linda Easterbrook, Sandra Smith, Neville Pope, Matthew Aldridge, Gareth Humphries, Holger Schuhmann, Didier Ngabo, Emma Rayner, Ashley Otter and 14 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Hyperimmune Globulins in COVID-19.Current topics in microbiology and immunology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Stephen Findlay-WilsonUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Linda EasterbrookUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Sandra SmithInternational Therapeutic Proteins Ltd, Longford, TAS, 7301, Australia.
Neville PopeInternational Therapeutic Proteins Ltd, Goleigh Farm, Selborne, GU34 3SE, Hampshire, UK.
Matthew AldridgeMicroPharm Ltd, Station Road, Newcastle Emlyn, SA38 9BY, UK.
Gareth HumphriesNative Antigen Company, Langford Locks, Kidlington, Oxford, OX5 1LH, UK.
Holger SchuhmannNative Antigen Company, Langford Locks, Kidlington, Oxford, OX5 1LH, UK.
Didier NgaboUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Emma RaynerUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Ashley OtterUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Thomas ColemanUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Bethany HicksUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Rachel HalkerstonUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Kostis ApostolakisUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Stephen TaylorUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Susan FotheringhamUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Amanda HortonUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Irene CanoCejasUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Matthew WandUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Julia A TreeUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Mark SuttonUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Victoria GrahamUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Roger HewsonUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Stuart DowallUK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK. stuart.dowall@ukhsa.gov.uk.

Funding

Department of HealthMedical Research Council MC_PC_19077
6 · The paper itself

Abstract

The development of new therapies against SARS-CoV-2 is required to extend the toolkit of intervention strategies to combat the global pandemic. In this study, hyperimmune plasma from sheep immunised with whole spike SARS-CoV-2 recombinant protein has been used to generate candidate products. In addition to purified IgG, we have refined candidate therapies by removing non-specific IgG via affinity binding along with fragmentation to eliminate the Fc region to create F(ab')

Indexed as

COVID-19SARS-CoV-2AnimalsCricetinaeImmunization, PassiveImmunoglobulin GKineticsSheepImmunoglobulin G

Identifiers

PMID37626085
PMCPMC10457378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.